Ke Cheng, Alan L. Kaganov Professor of Biomedical Engineering at Columbia University, shared a post on X about a recent article he and his colleagues co-authored, adding:
“Congratulations to Shuo Liu on the publication in Nature Biotechnology. An elegant and impactful study showcasing the power of engineered exosomes to overcome immunotherapy resistance.”
Title: Engineering bispecific exosome activators of T cells to target immune checkpoint inhibitor-resistant metastatic melanoma
Authors: Shuo Liu, Mengrui Liu, Zhenzhen Wang, Shiqi Hu, Kaiyue Zhang, Chao Lu, Xiao Cheng, Ming Shen, Jianing Bi, Dashuai Zhu, Ke Cheng
Read the Full Article on Nature Biotechnology
More posts about Immunotherapy.
